Fenofibrate or omega-3 fatty acid use is associated with lower long term outcomes from propensity matched analysis of 141972 patients with diabetes in Korean national health insurance cohort

Abstract

Abstract Background We investigated the clinical effectiveness of fenofibrate or omega 3-fatty acid in patients with diabetes for long term. Methods Using Korean National Health Insurance data base, 141972 eligible patients with diabetes were selected. We divided the patients into 2 groups with propensity matching 1:2 ratio, fenofibrate/omega 3 fatty acid users (Fen-O, n=42353) or no users (n=14880). We followed up for 6-years for primary endpoint of death, myocardial infarction (MI), stroke and individual outcomes including cardiac death. Results Primary endpoint was significantly lower in Fen-O group as compared to no users, 2.35% vs. 1.58% (HR 0.673, CI: 0.633–0.715, P<0.001) in crude and 2.35% vs. 1.58% (HR 0.641, CI: 0.565–0.728) after adjusting age, sex, medical history analysis, body mass index, LDL-C and HDL-C). All cause death (0.76% vs. 1.24% [HR 0.664, CI: 0.625–0.706], p<0.0001), cardiac death (0.11% vs. 1.19% [HR 0.610, CI: 0.486–0.765, p=0.0001) and stroke (0.57% vs. 0.79%, [HR 0.723, CI: 0.594–0.881, P=0.0013) were significantly lower in Fen-O group. In the survival analysis, Fen-O group showed significantly lower primary outcome rate which is proportional with the days of intaking fenofibrate or omega 3 fatty acid (log rank <0.001), Conclusions Use of fenofibrate or omega 3 fatty-acid was associated with lower rate of composite of death, MI, stroke in diabetes patient for 6 year follow-up with large population. Funding Acknowledgement Type of funding source: None